OraSure Technologies, Inc. (NASDAQ:OSUR) Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total transaction of $419,294.01. Following the sale, the director now owns 59,749 shares in the company, valued at $1,073,689.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
OraSure Technologies, Inc. (OSUR) opened at $17.86 on Wednesday. The company has a market cap of $1,080.00, a P/E ratio of 35.02, a price-to-earnings-growth ratio of 5.10 and a beta of 1.42. OraSure Technologies, Inc. has a one year low of $10.75 and a one year high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The company had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The firm’s revenue was up 46.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.13 earnings per share. analysts expect that OraSure Technologies, Inc. will post 0.29 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. purchased a new position in OraSure Technologies in the third quarter valued at approximately $186,000. ARP Americas LLC purchased a new position in OraSure Technologies in the third quarter valued at approximately $221,000. Noesis Capital Mangement Corp purchased a new position in OraSure Technologies in the third quarter valued at approximately $225,000. Shikiar Asset Management Inc. purchased a new position in OraSure Technologies in the fourth quarter valued at approximately $207,000. Finally, Piedmont Investment Advisors LLC purchased a new position in OraSure Technologies in the second quarter valued at approximately $216,000. Institutional investors own 89.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: “OraSure Technologies, Inc. (OSUR) Director Stephen S. Phd Tang Sells 23,333 Shares of Stock” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2018/02/21/orasure-technologies-inc-osur-director-stephen-s-phd-tang-sells-23333-shares-of-stock.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.